These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 3080696)

  • 1. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture.
    Snyder SH; D'Amato RJ
    Neurology; 1986 Feb; 36(2):250-8. PubMed ID: 3080696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin.
    D'Amato RJ; Lipman ZP; Snyder SH
    Science; 1986 Feb; 231(4741):987-9. PubMed ID: 3080808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals.
    Kopin IJ
    Adv Neurol; 1987; 45():137-44. PubMed ID: 3493621
    [No Abstract]   [Full Text] [Related]  

  • 5. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MPTP toxicity: implications for research in Parkinson's disease.
    Kopin IJ; Markey SP
    Annu Rev Neurosci; 1988; 11():81-96. PubMed ID: 3129982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW
    Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of MPTP and its pyridinium metabolites on monoamine uptake and on central catecholamine neurons in mice.
    Jonsson G; Nwanze E; Luthman J; Sundström E
    Acta Physiol Scand; 1986 Oct; 128(2):187-94. PubMed ID: 3535380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromelanin: a role in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Life Sci; 1987 Feb; 40(8):705-12. PubMed ID: 2880274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.
    Javitch JA; D'Amato RJ; Strittmatter SM; Snyder SH
    Proc Natl Acad Sci U S A; 1985 Apr; 82(7):2173-7. PubMed ID: 3872460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+.
    Nakamura S; Vincent SR
    Neurosci Lett; 1986 Apr; 65(3):321-5. PubMed ID: 3487052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental model of Parkinson disease: mechanisms and anatomo- pathological characteristics of MPTP neurotoxicity].
    Herrero MT; Luquín MR; Obeso JA
    Arch Neurobiol (Madr); 1992; 55(4):175-82. PubMed ID: 1417423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPTP: a pharmacological tool to study parkinsonism.
    Kulkarni SK; Mehta AK; Aley KO; Shukla VK
    Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys.
    Chiueh CC; Burns RS; Markey SP; Jacobowitz DM; Kopin IJ
    Life Sci; 1985 Jan; 36(3):213-8. PubMed ID: 3871241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism.
    Markey SP; Johannessen JN; Chiueh CC; Burns RS; Herkenham MA
    Nature; 1984 Oct 4-10; 311(5985):464-7. PubMed ID: 6332988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of Monoamine Oxidase in the Nigrostriatal System at Presymptomatic and Early Symptomatic Stages of Parkinsonism in Mice.
    Khakimova GR; Kozina EA; Buneeva OA; Aksenova LN; Medvedev AE; Ugryumov MV
    Bull Exp Biol Med; 2015 Aug; 159(4):456-8. PubMed ID: 26388575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
    N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.